Company / Accounts Receivable
Avalo Therapeutics, Inc. Accounts Receivable History
FY2017-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
-
FY2022
5-year range
$0 / $1.1M
FY2018-FY2022
Trend
-100.0%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $2M to $0 over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2022, accounts receivable decreased 100.0% year-over-year.
- Peak accounts receivable was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.59 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | $0 | -100.0% |
| FY2021 | $1.1M | -51.3% |
| FY2020 | $2.2M | +117.3% |
| FY2019 | $1.0M | +21.8% |
| FY2018 | $822.3K | -72.0% |
| FY2017 | $2.9M | - |
As of FY2022 · SEC Form 10-K · Last checked Jun 21, 2026